Biogen is under investigation by Pomerantz LLP for potential securities fraud following the announcement that its Alzheimer's drug trial missed the primary dose-response endpoint, despite being described as "compelling." The news caused Biogen's stock to fall 6.43% on May 14, 2026. Investors are being advised to contact the law firm for possible class action participation. This investigation could impact Biogen's reputation and investor confidence moving forward.
New modeling from Boehringer Ingelheim's FIBRONEER™ Phase III trials suggests that nerandomilast, an oral PDE4B inhibitor, could significantly extend median survival in adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosi...
Biogen has agreed to acquire RayThera Inc. for up to $1 billion, including upfront and milestone payments. This acquisition adds multiple anti-inflammatory drug candidates to Biogen's immunology portfolio, with the lead asset expected to enter Phase ...
